NEWS
ARISTA NETWORKS INTRODUCES AI-DRIVEN NETWORK IDENTITY
Arista Networks , a leading provider of cloud networking solutions , has announced a clouddelivered , AI-driven network identity service for enterprise security and IT operations . Based on Arista ’ s flagship CloudVision platform , Arista Guardian for Network Identity ( CV AGNI ) expands Arista ’ s Zero Trust networking approach to enterprise security . CV AGNI helps to secure IT operations with simplified deployment and cloud-scale for all enterprise network users , their associated endpoints and Internet-of-Things ( IoT ) devices .
" Proliferation of IoT devices in the healthcare network creates a huge management and security challenge for our IT and security operations .
The ease of securely onboarding devices on the network by CV AGNI and its integration with Medigate by Claroty for device profiling greatly simplifies this problem for a healthcare network ,” said Aaron Miri , CIO of Baptist Healthcare .
While enterprise networks have seen massive transformation in recent years with the adoption of the cloud and the acceleration of a post-pandemic , perimeter-less enterprise , Network Access Control ( NAC ) solutions have changed little for decades . Traditional NAC solutions continue to suffer from the complexity of on-premises deployment and administration and have been unable to adapt to the explosion of SaaS-based identity stores , users , devices and their associated profiles across the enterprise .
CloudVision AGNI takes a novel approach to enterprise network identity management . Built on a modern , cloudnative microservices architecture , the CV AGNI solution leverages AI / ML to greatly simplify the secure onboarding and troubleshooting for users and devices and the management of ever-expanding security policies .
CLINICAL TRIAL FINDS ULTRASOUND STIMULATION OF THE SPLEEN REDUCES INFLAMMATION IN HUMANS
Researchers at The Feinstein Institutes for Medical Research , in collaboration with GE Research , have harnessed ultrasound technology to noninvasively reduce inflammation in the body . Results from human studies , published in the Brain Stimulation , point to the possibility of using bioelectronic medicine and neuromodulation to treat inflammatory diseases traditionally treated only with drugs . circulates in the bloodstream . They found that spleen FUS has an anti-inflammatory effect , lowering TNF production from blood cells for more than two hours , with TNF returning to baseline levels by 24 hours after stimulation ; sham stimulation does not affect TNF production .
“ From diabetes and obesity to cardiovascular diseases and cancer , inflammation is a major pathogenic mechanism in many diseases ,” said Dr Zanos , Associate Professor at the Feinstein Institutes ’ Institute of Bioelectronic Medicine . “ These firstin-human results are exciting because they demonstrate the potential ultrasound stimulation therapy holds to treat diseases , non-invasively , with existing technology .”
Led by Feinstein Institutes ’ Sangeeta S . Chavan , PhD , and Stavros Zanos , MD , PhD , along with GE Research ’ s Christopher Puleo , PhD , Senior Principal Engineer and Jeff Ashe , MS , Principal Engineer in biomedical electronics , delivered spleen-focused ultrasound stimulation ( FUS ) or sham stimulation , to 70 healthy participants . Through careful blood analyses and measurements , they investigated the levels of endotoxin-induced tumour necrosis factor ( TNF ), an inflammatory protein that is released by white blood cells and
www . intelligenthealth . tech 11